Jian L Campian
Overview
Explore the profile of Jian L Campian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1869
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riviere-Cazaux C, Graser C, Warrington A, Hoplin M, Andersen K, Malik N, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39786485
Background: While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However,...
2.
Riviere-Cazaux C, Keough M, Zuccato J, Kumar R, Schulz S, Warrington A, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39786477
Cerebrospinal fluid (CSF) has emerged as a valuable liquid biopsy source for glioma biomarker discovery and validation. CSF produced within the ventricles circulates through the subarachnoid space, where the composition...
3.
Lim S, Clarke N, Maloney S, Sener U, Caron S, Kizilbash S, et al.
J Neurooncol
. 2025 Jan;
172(1):273-280.
PMID: 39747716
Purpose: Bevacizumab, an anti-VEGF monoclonal antibody, has become a mainstay therapeutic in the management of malignant glioma. It is unknown if the risk of intracranial hemorrhage (ICH), a major complication...
4.
Riviere-Cazaux C, Dong X, Mo W, Kumar R, Dai C, Carlstrom L, et al.
Clin Cancer Res
. 2024 Dec;
31(5):881-889.
PMID: 39715486
Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients...
5.
Sarkaria J, Ballman K, Kizilbash S, Sulman E, Giannini C, Friday B, et al.
JAMA Oncol
. 2024 Oct;
10(12):1637-1644.
PMID: 39480453
Importance: The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields. Objectives: To evaluate the combination of veliparib and temozolomide in...
6.
Valerius A, Webb L, Thomsen A, Lehrer E, Breen W, Campian J, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408897
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with...
7.
Webb L, Webb M, Campian J, Caron S, Ruff M, Uhm J, et al.
Medicine (Baltimore)
. 2024 Jul;
103(27):e38794.
PMID: 38968484
Background: Extracranial metastases occur in <2% of cases of glioblastoma (GBM). When metastases do occur, bone is the most common destination. Herein, we review clinical characteristics of GBM patients with...
8.
Riviere-Cazaux C, Graser C, Warrington A, Hoplin M, Andersen K, Malik N, et al.
medRxiv
. 2024 May;
PMID: 38798641
One Sentence Summary: Glioma cerebrospinal fluid (CSF) accessed intra-operatively and longitudinally via devices can reveal impacts of treatment and anatomical location.
9.
Huang J, Campian J, DeWees T, Skrott Z, Mistrik M, Johanns T, et al.
Int J Radiat Oncol Biol Phys
. 2024 May;
120(3):738-749.
PMID: 38768767
Purpose: This phase 1/2 study aimed to evaluate the safety and preliminary efficacy of combining disulfiram and copper (DSF/Cu) with radiation therapy (RT) and temozolomide (TMZ) in patients with newly...
10.
Ser M, Webb M, Sener U, Campian J
J Immunother Precis Oncol
. 2024 May;
7(2):97-110.
PMID: 38721406
Glioblastoma (GBM) is the most prevalent malignant tumor of the central nervous system. The prognosis of GBM is grim, with a median overall survival of 14.6 months and only 6.9%...